NTCOC
NBIX icon

Northern Trust Company of Connecticut’s Neurocrine Biosciences NBIX Stock Holding History

Northern Trust Company of Connecticut’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$634K Sell
67,926
-4,200
-6% -$41K ﹤0.01% 1502
2013
Q3 		$816K Sell
72,126
-8,500
-11% -$117K 0.01% 1407
2013
Q2 		$1.08M Buy
+80,626
New +$990K 0.01% 1265

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Northern Trust Company of Connecticut's NBIX Position: Q4 2013 in Review

Northern Trust Company of Connecticut reduced its Neurocrine Biosciences (NBIX) stake by 5.8% in Q4 2013, selling an estimated $41K and leaving 67,926 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

Northern Trust Company of Connecticut first reported a position in NBIX in Q2 2013 and has held it in 3 quarters since. The position peaked at $1.08M in Q2 2013. 117 funds tracked by Wall St. Rank hold NBIX as of Q4 2013.

  • Northern Trust Company of Connecticut held 67,926 shares of Neurocrine Biosciences worth $634K as of Q4 2013.
  • Northern Trust Company of Connecticut sold 4,200 Neurocrine Biosciences shares in Q4 2013, an estimated $41K.
  • Neurocrine Biosciences made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1502 holding.
  • Northern Trust Company of Connecticut first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 3 quarters since.
  • Northern Trust Company of Connecticut's Neurocrine Biosciences position peaked at $1.08M in Q2 2013.
  • 117 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.